December 02, 2021
Video
Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, addresses major unmet needs in Fabry disease, ranging from uncontrolled pain to irreversible damage prior to treatment initiation.
Article
Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).
Testing for spinal muscular atrophy in an Australian newborn screening program identified patients across socioeconomic and cultural demographics, mitigating inequity and providing patients with access to multidisciplinary treatment.
A systematic review showed that a high fractional exhaled nitric oxide (FeNO) value before starting inhaled corticosteroid (ICS) therapy may be associated with higher response rates in patients with chronic cough.
Victoria Ly, MD, MPH, outlines one method of tackling vision screening follow-up rate disparities among children in Arkansas.
Processes used to identify and understand genetic markers detailing the prognosis and responsiveness to therapy in adrenocortical carcinoma (ACC) face a number of implementation barriers, limiting the potential for individualized ACC management.
In a local market with multiple accountable care organizations and multiple Medicare Advantage plans, how do we administratively set rates that are localized enough so that they do not drive consolidation?
Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.
The first case of the Omicron COVID-19 variant has been detected in the United States; Supreme Court justices signal support for upholding Mississippi’s abortion law; a federal judge blocks the Biden administration’s vaccine mandate for health care workers.
Adriaan Voors, MD, discusses possible mechanisms of action of empagliflozin that produce such beneficial results among patients with heart failure, in an interview about the EMPULSE trial prior to this year’s American Heart Association Scientific Sessions.
